A. Vasoconstrictors (such as epinephrine) cause local vasoconstriction, which reduces blood flow at the injection site. This slows the rate at which the anesthetic is absorbed into the systemic circulation. As a result, plasma drug levels remain lower, decreasing the likelihood of systemic toxicity (e.g., CNS effects like seizures or cardiovascular effects such as arrhythmias). This is particularly important with potent local anesthetics like lidocaine or bupivacaine, where high systemic levels can be dangerous. B. Vasoconstrictors do not prevent bradycardia. Instead, they stimulate adrenergic receptors, which can lead to increased heart rate (tachycardia) and elevated blood pressure if absorbed systemically. Therefore, they are used cautiously in clients with cardiovascular disease. Preventing bradycardia is not a therapeutic goal of adding vasoconstrictors. C. By decreasing local blood flow, vasoconstrictors delay the removal of the anesthetic from the injection site, allowing it to remain in contact with nerve fibers longer. This prolongs the duration of anesthesia, which is beneficial during longer procedures and reduces the need for repeated dosing. D. Vasoconstrictors actually decrease (not enhance) absorption into systemic circulation. This is the key mechanism behind both reduced toxicity and prolonged action. Enhanced absorption would increase systemic drug levels, which is the opposite of the intended effect. E. Because vasoconstrictors slow drug absorption and keep the anesthetic localized, they prolong rather than shorten the duration of action. Shortening duration would require faster systemic uptake, which vasoconstrictors specifically prevent.